R303
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 62
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.590
- HEDGEHOG_SIGNALING+0.550
- IL6_JAK_STAT3_SIGNALING+0.550
- INFLAMMATORY_RESPONSE+0.510
- ANGIOGENESIS+0.500
- COMPLEMENT+0.480
- COAGULATION+0.460
Top 10 suppressed
- PEROXISOME-0.150
- BILE_ACID_METABOLISM-0.130
- HEME_METABOLISM-0.070
- PANCREAS_BETA_CELLS-0.060
- DNA_REPAIR-0.050
- FATTY_ACID_METABOLISM-0.040
- ADIPOGENESIS-0.020
- OXIDATIVE_PHOSPHORYLATION-0.010
- PROTEIN_SECRETION-0.010
- ESTROGEN_RESPONSE_EARLY+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943031 | — | — | 0.903 |
| 2 | C3L-02951 | — | cohortSQ1 | 0.901 |
| 3 | TCGA-FD-A62N-01A-11R-A30C-07 | — | — | 0.900 |
| 4 | TCGA-66-2744-01A-01R-0980-07 | — | cohortA1 | 0.892 |
| 5 | BS_J1AB8PMA | Med | Medulloblastoma | 0.888 |
| 6 | MNG1029 | — | — | 0.884 |
| 7 | AUR-AFUI-TTP1-A-1-0-R-A743-41 | — | C | 0.884 |
| 8 | R409 | — | — | 0.883 |
| 9 | MDT-AP-2086 | Med | Medulloblastoma | 0.882 |
| 10 | R317 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.620 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |